Tebao Bio: Net profit of 1.038 billion yuan in 2025, a year-on-year increase of 25.39%

Tebao Biotech releases earnings forecast, achieving a total operating revenue of 3.696 billion yuan in 2025, a year-on-year increase of 31.18%; net profit of 1.038 billion yuan, a year-on-year increase of 25.39%. During the reporting period, as the company’s product Pagrabin combined with nucleoside (acid) analogs was approved for additional indications for the continuous clearance of HBsAg in adult patients with chronic hepatitis B, and as scientific evidence related to clinical cure of hepatitis B continued to accumulate, Pagrabin, as the world’s first drug with clinical cure of hepatitis B as a treatment goal, further solidified its cornerstone position in combination therapy for clinical cure of chronic hepatitis B. The new product Yipei Sheng was approved for listing and included in the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List.” With its advantages of safety, efficacy, and convenience, the product’s market promotion has been progressing smoothly.